Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery and Postoperative Radiotherapy for Lymph Node-Positive Biliary Tract Cancer
NCT07893392Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, tegafur in biliary tract cancer (BTC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Oct 2026; status: recruiting.
02
Drugs
capecitabinetegafur
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07893392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893392.